Evidence map›Paper›PMID 34812900›Full record

ArticlePsychopharmacology2022

Reducing effect of the novel positive allosteric modulator of the GABA

Irene Lorrai, Chase Shankula, Jorge Marquez Gaytan, Tomoya Kawamura, Paola Maccioni, Claudia Mugnaini, Federico Corelli, Gian Luigi Gessa, Pietro Paolo Sanna, Giancarlo Colombo

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Delving into the reducing effects of the GABAAlcohol (Fayetteville, N.Y.) · 2023
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Irene LorraiDepartment of Immunology and Microbiology, The Scripps Research Institute, 10550 North Torrey Pines Road, MB-114, La Jolla, CA, 92037, USA. ilorrai@scripps.edu.ORCID http://orcid.org/0000-0003-1452-481X
Chase ShankulaDepartment of Immunology and Microbiology, The Scripps Research Institute, 10550 North Torrey Pines Road, MB-114, La Jolla, CA, 92037, USA.
Jorge Marquez GaytanDepartment of Immunology and Microbiology, The Scripps Research Institute, 10550 North Torrey Pines Road, MB-114, La Jolla, CA, 92037, USA.
Tomoya KawamuraDepartment of Immunology and Microbiology, The Scripps Research Institute, 10550 North Torrey Pines Road, MB-114, La Jolla, CA, 92037, USA.
Paola MaccioniNeuroscience Institute, Section of Cagliari, National Research Council of Italy, I-09042, Monserrato, CA, Italy.
Claudia MugnainiDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, I-53100, Siena, SI, Italy.
Federico CorelliDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, I-53100, Siena, SI, Italy.
Gian Luigi GessaDepartment of Biomedical Sciences, University of Cagliari, (CA), I-09042, Monserrato, Italy.
Pietro Paolo SannaDepartment of Immunology and Microbiology, The Scripps Research Institute, 10550 North Torrey Pines Road, MB-114, La Jolla, CA, 92037, USA.
Giancarlo ColomboNeuroscience Institute, Section of Cagliari, National Research Council of Italy, I-09042, Monserrato, CA, Italy.
Scripps Research Institute · USNational Academies of Sciences, Engineering, and Medicine · USUniversity of Siena · ITUniversity of Cagliari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleBinge drinking (BD) is a widespread drinkingpattern that may contribute to promote the development of alcohol use disorder (AUD). The comprehension of its neurobiological basis and the identification of molecules that may prevent BD are critical. Preclinical studies demonstrated that positive allosteric modulators (PAMs) of the GABA

objectivesThe present study investigated whether the "anti-alcohol" properties of COR659 extend to binge-like drinking in rodents.

methodsCOR659 was tested on the "drinking in the dark" (DID) paradigm in C57BL/6J mice and the 4-bottle "alcohol [10%, 20%, 30% (v/v)] versus water" choice regimen with limited and unpredictable access to alcohol in sP rats.

resultsAcute administration of non-sedative doses of COR659 (10, 20, and 40 mg/kg; i.p.) effectively and selectively suppressed the intake of intoxicating amounts of alcohol (> 2 g/kg) consumed by C57BL/6J mice and sP rats exposed to these binge-like drinking experimental procedures.

conclusionsThe present data demonstrate the ability of COR659 to suppress binge-like drinking in rodents and strengthen the hypothesis that GABA

Indexed as

Alcohol DrinkingReceptors, GABA-BAnimalsEthanolgamma-Aminobutyric AcidMaleMiceMice, Inbred C57BLRatsSelf AdministrationEthanolgamma-Aminobutyric AcidReceptors, GABA-B4-bottle “alcohol versus water” choice regimenBinge drinkingC57BL/6J miceCOR659“Drinking in the dark”Positive allosteric modulators of the GABAB receptorSardinian alcohol-preferring rats

Identifiers

PMID34812900
OpenAlexW3216288475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.